The Current and Future of Biomarkers of Immune Related Adverse Events.
Autoantibodies
Chemokines
Cytokines
Immune checkpoint-inhibitors
Immune-related adverse events
Microbiome
Journal
Rheumatic diseases clinics of North America
ISSN: 1558-3163
Titre abrégé: Rheum Dis Clin North Am
Pays: United States
ID NLM: 8708093
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
26
4
2024
Statut:
ppublish
Résumé
With their groundbreaking clinical responses, immune checkpoint inhibitors (ICIs) have ushered in a new chapter in cancer therapeutics. However, they are often associated with life-threatening or organ-threatening autoimmune/autoinflammatory phenomena, collectively termed immune-related adverse events (irAEs). In this review, we will first describe the mechanisms of action of ICIs as well as irAEs. Next, we will review biomarkers for predicting the development of irAEs or stratifying risks.
Identifiants
pubmed: 38670721
pii: S0889-857X(24)00004-8
doi: 10.1016/j.rdc.2024.01.004
pii:
doi:
Substances chimiques
Biomarkers
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-227Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.